| Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report … JJM Van Dongen, AW Langerak, M Brüggemann, PAS Evans, M Hummel, ... Leukemia 17 (12), 2257-2317, 2003 | 3474 | 2003 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 930 | 2012 |
| New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis … E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ... Blood, The Journal of the American Society of Hematology 110 (7), 2586-2592, 2007 | 587 | 2007 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 567 | 2010 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ... Blood 108 (7), 2165-2172, 2006 | 530 | 2006 |
| Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103, 2017 | 525 | 2017 |
| Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma J Martinez-Lopez, JJ Lahuerta, F Pepin, M González, S Barrio, R Ayala, ... Blood, The Journal of the American Society of Hematology 123 (20), 3073-3079, 2014 | 471 | 2014 |
| EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations AW Langerak, PJTA Groenen, M Brüggemann, K Beldjord, C Bellan, ... Leukemia 26 (10), 2159-2171, 2012 | 455 | 2012 |
| Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics R Garcıa-Sanz, A Orfao, M Gonzalez, MD Tabernero, J Bladé, MJ Moro, ... Blood, The Journal of the American Society of Hematology 93 (3), 1032-1037, 1999 | 447 | 1999 |
| International prognostic scoring system for Waldenström macroglobulinemia P Morel, A Duhamel, P Gobbi, MA Dimopoulos, MV Dhodapkar, J McCoy, ... Blood, The Journal of the American Society of Hematology 113 (18), 4163-4170, 2009 | 439 | 2009 |
| Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle-and high-income countries BJA: British Journal of Anaesthesia 117 (5), 601-609, 2016 | 436 | 2016 |
| International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ... Journal of clinical oncology 31 (18), 2347, 2013 | 421 | 2013 |
| Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study N Raje, E Terpos, W Willenbacher, K Shimizu, R García-Sanz, B Durie, ... The Lancet Oncology 19 (3), 370-381, 2018 | 352 | 2018 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 328 | 2014 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 324 | 2019 |
| Improved reliability of lymphoma diagnostics via PCR-based clonality testing:—Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 J Van Krieken, AW Langerak, EA Macintyre, M Kneba, E Hodges, ... Leukemia 21 (2), 201-206, 2007 | 320 | 2007 |
| Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and … M Ocqueteau, A Orfao, J Almeida, J Blade, M Gonzalez, R García-Sanz, ... The American journal of pathology 152 (6), 1655, 1998 | 299 | 1998 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 297 | 2018 |
| Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases R García‐Sanz, S Montoto, A Torrequebrada, AG De Coca, J Petit, ... British journal of haematology 115 (3), 575-582, 2001 | 293 | 2001 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, J Mariano Hernández, ... Leukemia 27 (8), 1722-1728, 2013 | 285 | 2013 |
Enrique M. OcioHospital Universitario Marqués de Valdecilla在 unican.es 的电子邮件经过验证
